Collateral hypersensitivity between ZY19489 and piperaquine neutralizes PfCRT-mediated drug efflux and Plasmodium falciparum resistance

Abstract New antimalarial drugs are needed to combat the current emergence and spread of Plasmodium falciparum parasite resistance to artemisinin-based combination therapies. Here, we characterize ZY19489, a triaminopyrimidine presently in a Phase Ib clinical trial. Asexual blood-stage parasites pre...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	John Okombo, Tolla Ndiaye, Tarrick Qahash, Igor M. R. Moura, Eva Gil-Iturbe, Laura M. Hagenah, Jessica L. Bridgford, Vinicius Bonatto, Kurt E. Ward, Tomas Yeo, Sunil K. Narwal, Lily V. Orta, Isla Anderson, Satish K. Dhingra, Charisse Flerida A. Pasaje, Heekuk Park, Jonathan Kim, Rafael V. C. Guido, Maria Belén Jiménez-Diaz, Iñigo Angulo-Barturen, Jacquin C. Niles, Filippo Mancia, Anne-Catrin Uhlemann, Sachel Mok, Matthias Quick, Elizabeth A. Winzeler, Didier Leroy, Manuel Llinás, Vandana Thathy, David A. Fidock
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Nature Portfolio 2026-04-01
Reeks:	Nature Communications
Online toegang:	https://doi.org/10.1038/s41467-026-70914-1
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!